纳米载体辅助静脉药物输送的基于多尺度物理的化模型
Nicolae-Viorel Buchete1,2, Iwona Cicha3, Sutapa Dutta1,2
1School of Physics, University College Dublin, Dublin, Ireland.
Frontiers in drug delivery
|August 21, 2025
概括
使用in silico建模的药物纳米载体的合理设计可以增强血管内药物输送 (IVDD). 本综述讨论了为有效的纳米载体评估制定标准化的临床前试验框架.
科学领域:
- 药理学
- 生物医学工程
- 计算科学
背景情况:
- 血管内药物输送 (IVDD) 依赖于纳米载体以提高治疗效果.
- 目前对纳米载体的临床前试验耗时且昂贵.
- 在模型中提供了优化纳米载体设计和评估的有希望的替代方案.
研究的目的:
- 审查基于纳米载体的IVDD的现状.
- 讨论在临床前试验中开发基于物理的多尺度建模框架.
- 突出了对纳米载体评估进行标准化和验证的模拟工具的需求.
主要方法:
- 对纳米载体研究的现有in silico工具和框架进行文献审查.
- 讨论适用于IVDD系统的多尺度建模方法.
- 根据实验数据对in silico模型的验证要求的分析.
主要成果:
- 在模型工具可以显著提高药物纳米载体的合理设计.
- 在临床前试验的标准化框架对于高效的纳米载体开发至关重要.
- 现有的建模方法需要进一步开发和验证用于IVDD应用.
结论:
- 为了推进基于纳米载体的IVDD,开发和验证一个全面的临床前试验框架至关重要.
- 这种框架将使纳米载体的临床前评估更有效,更准确,更具成本效益.
- 这种方法支持将传统的临床前试验用先进的模拟来改进纳米医学开发的愿景.
相关概念视频
00:57Physiological Pharmacokinetic Models: Blood Flow-Limited Versus Diffusion-Limited Models
142
Physiological pharmacokinetic models, often called flow-limited or perfusion models, typically assume a swift drug distribution between tissue and venous blood, creating a rapid drug equilibrium. This premise is based on the idea that drug diffusion is extremely fast, and the cell membrane presents no barrier to drug permeation. In this scenario, where no drug binding occurs, the drug concentration in the tissue equals that of the venous blood leaving the tissue. This greatly simplifies the...
142
01:07Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
79
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
79